Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy

por Sazuka, Tomokazu, Nihei, Naoki, Nakamura, Kazuyoshi, Sakamoto, Shinichi, Fukasawa, Satoshi, Komaru, Atsushi, Ueda, Takeshi, Igarashi, Tatsuo, Ichikawa, Tomohiko
Publicado 2015

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a r...

por Fukasawa, Satoshi, Suzuki, Hiroyoshi, Kawaguchi, Kazushiro, Noguchi, Hidehisa, Enjo, Kentaro, Tran, Namphuong, Todd, Mary, Fizazi, Karim, Matsubara, Nobuaki
Publicado 2018

Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I...

por Tomita, Yoshihiko, Kimura, Go, Fukasawa, Satoshi, Numakura, Kazuyuki, Sugiyama, Yutaka, Yamana, Kazutoshi, Naito, Sei, Kabu, Koki, Tajima, Yohei, Oya, Mototsugu
Publicado 2021

Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patien...

por Tomita, Yoshihiko, Kimura, Go, Fukasawa, Satoshi, Numakura, Kazuyuki, Sugiyama, Yutaka, Yamana, Kazutoshi, Naito, Sei, Kaneko, Hirokazu, Tajima, Yohei, Oya, Mototsugu
Publicado 2021

Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Jap...

por Tomita, Yoshihiko, Kimura, Go, Fukasawa, Satoshi, Numakura, Kazuyuki, Sugiyama, Yutaka, Yamana, Kazutoshi, Naito, Sei, Kaneko, Hirokazu, Tajima, Yohei, Oya, Mototsugu
Publicado 2021

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE,...

por Suzuki, Hiroyoshi, Shin, Toshitaka, Fukasawa, Satoshi, Hashine, Katsuyoshi, Kitani, Sumiko, Ohtake, Noriyuki, Shibayama, Kazuhiro, Tran, Namphuong, Mundle, Suneel, Fizazi, Karim, Matsubara, Nobuaki
Publicado 2020

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan

por Kosaka, Takeo, Uemura, Hiroji, Sumitomo, Makoto, Harada, Kenichi, Sugimoto, Mikio, Hayashi, Narihiko, Yoshimura, Kazuhiro, Fukasawa, Satoshi, Ecstein-Fraisse, Evelyne, Sunaga, Yoshinori, Oya, Mototsugu
Publicado 2019

Development and External Validation of a Nomogram Predicting the Probability of Significant Gleason Sum Upgrading among Japanese Patients with Localized Prostate Cancer

por Imamoto, Takashi, Utsumi, Takanobu, Takano, Makoto, Komaru, Atsushi, Fukasawa, Satoshi, Suyama, Takahito, Kawamura, Koji, Kamiya, Naoto, Miura, Junichiro, Suzuki, Hiroyoshi, Ueda, Takeshi, Ichikawa, Tomohiko
Publicado 2011

Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study

por Oya, Mototsugu, Tomita, Yoshihiko, Fukasawa, Satoshi, Shinohara, Nobuo, Habuchi, Tomonori, Rini, Brian I., Fujii, Yosuke, Kamei, Yoichi, Umeyama, Yoshiko, Bair, Angel H., Uemura, Hirotsugu
Publicado 2017

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study

por Ozono, Seiichiro, Tsukamoto, Taiji, Naito, Seiji, Horie, Shigeo, Ohashi, Yasuo, Uemura, Hiroji, Yokomizo, Yumiko, Fukasawa, Satoshi, Kusuoka, Hidehito, Akazawa, Rio, Saito, Masako, Akaza, Hideyuki
Publicado 2018

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study

por Tomita, Yoshihiko, Fukasawa, Satoshi, Oya, Mototsugu, Uemura, Hirotsugu, Shinohara, Nobuo, Habuchi, Tomonori, Rini, Brian I., Chen, Ying, Bair, Angel H., Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki
Publicado 2016

Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study

por Iguchi, Taro, Kimura, Go, Fukasawa, Satoshi, Suzuki, Hiroyoshi, Uemura, Hiroji, Nishimura, Kazuo, Matsumoto, Hiroaki, Yokomizo, Akira, Armstrong, Andrew J, Rosbrook, Brad, Sugg, Jennifer, Baron, Benoit, Chen, Lucy, Kunieda, Futoshi, Stenzl, Arnulf
Publicado 2021

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

por Eto, Masatoshi, Takagi, Toshio, Kimura, Go, Fukasawa, Satoshi, Tamada, Satoshi, Miura, Yuji, Oya, Mototsugu, Sassa, Naoto, Anai, Satoshi, Nozawa, Masahiro, Sakai, Hideki, Perini, Rodolfo, Yusa, Wataru, Ikezawa, Hiroki, Narita, Tomoyuki, Tomita, Yoshihiko
Publicado 2022

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

por Akaza, Hideyuki, Uemura, Hirotsugu, Tsukamoto, Taiji, Ozono, Seiichiro, Ogawa, Osamu, Sakai, Hideki, Oya, Mototsugu, Namiki, Mikio, Fukasawa, Satoshi, Yamaguchi, Akito, Uemura, Hiroji, Ohashi, Yasuo, Maeda, Hideki, Saito, Atsushi, Takeda, Kentaro, Naito, Seiji
Publicado 2016

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

por Nishiyama, Hiroyuki, Yamamoto, Yoshiaki, Sassa, Naoto, Nishimura, Kazuo, Fujimoto, Kiyohide, Fukasawa, Satoshi, Yokoyama, Minato, Enokida, Hideki, Takahashi, Kenichi, Tanaka, Yoshinobu, Imai, Kentaro, Shimamoto, Takashi, Perini, Rodolfo, Frenkl, Tara, Bajorin, Dean, Bellmunt, Joaquim
Publicado 2019

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study

por Tomita, Yoshihiko, Fukasawa, Satoshi, Shinohara, Nobuo, Kitamura, Hiroshi, Oya, Mototsugu, Eto, Masatoshi, Tanabe, Kazunari, Kimura, Go, Yonese, Junji, Yao, Masahiro, Motzer, Robert J., Uemura, Hirotsugu, McHenry, M. Brent, Berghorn, Elmer, Ozono, Seiichiro
Publicado 2017

A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel

por Noguchi, Masanori, Fujimoto, Kiyohide, Arai, Gaku, Uemura, Hiroji, Hashine, Katsuyoshi, Matsumoto, Hiroaki, Fukasawa, Satoshi, Kohjimoto, Yasuo, Nakatsu, Hideomi, Takenaka, Atsushi, Fujisawa, Masato, Uemura, Hirotsugu, Naito, Seiji, Egawa, Shin, Fujimoto, Hiroyuki, Hinotsu, Shiro, Itoh, Kyogo
Publicado 2021

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

por Matsubara, Nobuaki, Nagamori, Satsohi, Wakumoto, Yoshiaki, Uemura, Hirotsugu, Kimura, Go, Yokomizo, Akira, Kikukawa, Hiroaki, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Tsutsui, Hirokazu, Uemura, Hiroji
Publicado 2017

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases

por Uemura, Hirotsugu, Uemura, Hiroji, Nagamori, Satsohi, Wakumoto, Yoshiaki, Kimura, Go, Kikukawa, Hiroaki, Yokomizo, Akira, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Akagawa, Takashi, Matsubara, Nobuaki
Publicado 2019

A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data

por Hinata, Nobuyuki, Yonese, Junji, Masui, Satoru, Nakai, Yasutomo, Shirotake, Suguru, Tatsugami, Katsunori, Inamoto, Teruo, Nozawa, Masahiro, Ueda, Kosuke, Etsunaga, Toru, Osawa, Takahiro, Uemura, Motohide, Kimura, Go, Numakura, Kazuyuki, Yamana, Kazutoshi, Miyake, Hideaki, Fukasawa, Satoshi, Ochi, Kenya, Kaneko, Hirokazu, Uemura, Hirotsugu
Publicado 2020